You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFosphenytoin
Accession NumberDB01320
TypeSmall Molecule
GroupsApproved
DescriptionFosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Structure
Thumb
Synonyms
(3-Phosphoryloxymethyl)phenytoin
Cerebyx
Fosfenitoina
Fosphenytoin
Fosphenytoine
Fosphenytoinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cerebyxinjection, solution50 mg/mLintramuscular; intravenousPfizer Laboratories2013-10-28Not applicableUs
Cerebyxinjection, solution50 mg/mLintramuscular; intravenousPfizer Laboratories2013-10-28Not applicableUs
Cerebyxinjection, solution50 mg/mLintramuscular; intravenousPfizer Laboratories2013-10-28Not applicableUs
Cerebyxliquid75 mgintramuscular; intravenousErfa Canada 2012 Inc2000-03-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fosphenytoininjection, solution50 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2009-12-14Not applicableUs
Fosphenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousSun Pharma Global FZE2009-08-14Not applicableUs
Fosphenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousWest ward Pharmaceutical Corp2009-12-02Not applicableUs
Fosphenytoin Sodiuminjection50 mg/mLintramuscular; intravenousAmneal Pharmaceuticals of New York, LLC2013-05-17Not applicableUs
Fosphenytoin Sodiuminjection50 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2007-08-06Not applicableUs
Fosphenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousSun Pharma Global FZE2009-08-14Not applicableUs
Fosphenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravascularWest ward Pharmaceutical Corp2009-12-02Not applicableUs
Fosphenytoin Sodiuminjection50 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2007-08-06Not applicableUs
Fosphenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousHospira, Inc.2007-08-06Not applicableUs
Fosphenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousGenera Medix Inc.2007-08-06Not applicableUs
Fosphenytoin Sodiuminjection50 mg/mLintramuscular; intravenousAmneal Pharmaceuticals of New York, LLC2013-05-17Not applicableUs
Fosphenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousAmerican Regent, Inc.2010-07-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ProdilantinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fosphenytoin sodium
Thumb
  • InChI Key: GQPXYJNXTAFDLT-UHFFFAOYSA-L
  • Monoisotopic Mass: 406.03066202
  • Average Mass: 406.2375
DBSALT000296
Categories
UNIIB4SF212641
CAS number93390-81-9
WeightAverage: 362.2739
Monoisotopic: 362.066772734
Chemical FormulaC16H15N2O6P
InChI KeyInChIKey=XWLUWCNOOVRFPX-UHFFFAOYSA-N
InChI
InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)
IUPAC Name
[(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methoxy]phosphonic acid
SMILES
OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzolidines
Sub ClassImidazolidines
Direct ParentPhenylhydantoins
Alternative Parents
Substituents
  • 5-phenylhydantoin
  • Diphenylmethane
  • Phenylimidazolidine
  • Monoalkyl phosphate
  • Ureide
  • Benzenoid
  • Alkyl phosphate
  • Phosphoric acid ester
  • Organic phosphoric acid derivative
  • Organic phosphate
  • Monocyclic benzene moiety
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin.
PharmacodynamicsFosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. Following parenteral administration of fosphenytoin, fosphenytoin is converted to the anticonvulsant phenytoin by endogenous phosphatases. For every mmol of fosphenytoin administered, one mmol of phenytoin is produced. The pharmacological and toxicological effects of fosphenytoin include those of phenytoin.
Mechanism of actionFosphenytoin is a prodrug of phenytoin and accordingly, its anticonvulsant effects are attributable to phenytoin. Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas.
Related Articles
AbsorptionFosphenytoin is completely bioavailable following lM administration.
Volume of distribution
  • 4.3 to 10.8 L
Protein bindingExtensively bound (95% to 99%) to human plasma proteins, primarily albumin.
Metabolism

Hepatic.

SubstrateEnzymesProduct
Fosphenytoin
Not Available
PhenytoinDetails
Route of eliminationPhenytoin derived from administration of Cerebyx is extensively metabolized in the liver and excreted in urine primarily as 5-(p-hydroxyphenyl)-5-phenylhydantoin and its glucuronide; little unchanged phenytoin (1%–5% of the Cerebyx dose) is recovered in urine.
Half lifeFosphenytoin has a half-life of approximately 15 minutes.
ClearanceNot Available
ToxicityNausea, vomiting, lethargy, tachycardia, bradycardia, asystole, cardiac arrest, hypotension, syncope, hypocalcemia, metabolic acidosis, and death have been reported in cases of overdosage with fosphenytoin. The median lethal dose of fosphenytoin given intravenously in mice and rats was 156 mg PE/kg and approximately 250 mg PE/kg, or about 0.6 and 2 times, respectively, the maximum human loading dose on a mg/m2 basis. Signs of acute toxicity in animals included ataxia, labored breathing, ptosis, and hypoactivity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fosphenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00326
Fosphenytoin (Antiarrhythmic) Metabolism PathwayDrug metabolismSMP00618
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5244
Blood Brain Barrier+0.9215
Caco-2 permeable-0.639
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.7952
P-glycoprotein inhibitor IINon-inhibitor0.8466
Renal organic cation transporterNon-inhibitor0.8731
CYP450 2C9 substrateNon-substrate0.7094
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6873
CYP450 1A2 substrateNon-inhibitor0.8477
CYP450 2C9 inhibitorNon-inhibitor0.7802
CYP450 2D6 inhibitorNon-inhibitor0.8859
CYP450 2C19 inhibitorNon-inhibitor0.7169
CYP450 3A4 inhibitorNon-inhibitor0.7672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9083
Ames testNon AMES toxic0.614
CarcinogenicityNon-carcinogens0.7835
BiodegradationNot ready biodegradable0.9674
Rat acute toxicity2.4215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9578
hERG inhibition (predictor II)Non-inhibitor0.7299
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular; intravenous50 mg/mL
Liquidintramuscular; intravenous75 mg
Injectionintramuscular; intravenous50 mg/mL
Injection, solutionintramuscular; intravascular50 mg/mL
Prices
Unit descriptionCostUnit
Cerebyx 500 mg pe/10 ml vial8.63USD ml
Fosphenytoin 500 mg pe/10 ml0.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.145 mg/mLALOGPS
logP1.08ALOGPS
logP1.67ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)1.46ChemAxon
pKa (Strongest Basic)-9.7ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area116.17 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity87.05 m3·mol-1ChemAxon
Polarizability33.23 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Volker Kirsch, “Process for the preparation of sodium fosphenytoin.” U.S. Patent US20050272706, issued December 08, 2005.

US20050272706
General References
  1. Johnson J, Wrenn K: Inappropriate fosphenytoin use in the ED. Am J Emerg Med. 2001 Jul;19(4):293-4. [PubMed:11447516 ]
  2. Applebaum J, Levine J, Belmaker RH: Intravenous fosphenytoin in acute mania. J Clin Psychiatry. 2003 Apr;64(4):408-9. [PubMed:12716241 ]
  3. McCleane GJ: Intravenous infusion of fosphenytoin produces prolonged pain relief: a case report. J Pain. 2002 Apr;3(2):156-8. [PubMed:14622802 ]
  4. Browne TR, Kugler AR, Eldon MA: Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996 Jun;46(6 Suppl 1):S3-7. [PubMed:8649612 ]
  5. Luszczki JJ: Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009 Mar-Apr;61(2):197-216. [PubMed:19443931 ]
External Links
ATC CodesN03AB05
AHFS Codes
  • 28:12.12
PDB EntriesNot Available
FDA labelDownload (820 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of 2-HYDROXY-1,4-NAPHTHOQUINONE can be decreased when it is combined with Fosphenytoin.
2-mercaptobenzothiazoleThe serum concentration of 2-mercaptobenzothiazole can be decreased when it is combined with Fosphenytoin.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Fosphenytoin.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fosphenytoin.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Fosphenytoin.
AbirateroneThe serum concentration of Fosphenytoin can be increased when it is combined with Abiraterone.
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Fosphenytoin.
AcenocoumarolFosphenytoin may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fosphenytoin.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fosphenytoin.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Fosphenytoin.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Fosphenytoin.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be increased when combined with Fosphenytoin.
AdinazolamThe metabolism of Adinazolam can be increased when combined with Fosphenytoin.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Fosphenytoin.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fosphenytoin.
AlbendazoleThe metabolism of Albendazole can be increased when combined with Fosphenytoin.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Fosphenytoin.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Fosphenytoin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fosphenytoin.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fosphenytoin.
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Fosphenytoin.
AliskirenThe metabolism of Aliskiren can be increased when combined with Fosphenytoin.
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Fosphenytoin.
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Fosphenytoin.
AlogliptinThe metabolism of Alogliptin can be increased when combined with Fosphenytoin.
AlosetronThe metabolism of Alosetron can be increased when combined with Fosphenytoin.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fosphenytoin.
AlprazolamThe serum concentration of Fosphenytoin can be increased when it is combined with Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Alprazolam.
AmbrisentanThe metabolism of Ambrisentan can be increased when combined with Fosphenytoin.
AmbroxolThe metabolism of Ambroxol can be increased when combined with Fosphenytoin.
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Fosphenytoin.
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Fosphenytoin.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Fosphenytoin.
AmiodaroneFosphenytoin may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Fosphenytoin can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fosphenytoin.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fosphenytoin.
AmlodipineThe serum concentration of Fosphenytoin can be increased when it is combined with Amlodipine.
AmlodipineThe metabolism of Amlodipine can be increased when combined with Fosphenytoin.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fosphenytoin.
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Fosphenytoin.
AmorolfineThe serum concentration of Amorolfine can be decreased when it is combined with Fosphenytoin.
AmoxapineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Amoxapine.
AmoxicillinThe metabolism of Amoxicillin can be increased when combined with Fosphenytoin.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fosphenytoin.
Amphotericin BThe serum concentration of Amphotericin B can be decreased when it is combined with Fosphenytoin.
AmprenavirThe metabolism of Amprenavir can be increased when combined with Fosphenytoin.
AmrinoneThe serum concentration of Fosphenytoin can be increased when it is combined with Amrinone.
AN2690The serum concentration of AN2690 can be decreased when it is combined with Fosphenytoin.
AnidulafunginThe serum concentration of Anidulafungin can be decreased when it is combined with Fosphenytoin.
AntipyrineThe metabolism of Antipyrine can be increased when combined with Fosphenytoin.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Fosphenytoin.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Fosphenytoin.
AprepitantThe metabolism of Aprepitant can be increased when combined with Fosphenytoin.
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Fosphenytoin.
ArformoterolThe metabolism of Arformoterol can be increased when combined with Fosphenytoin.
ArgatrobanThe metabolism of Argatroban can be increased when combined with Fosphenytoin.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fosphenytoin.
ArmodafinilThe metabolism of Fosphenytoin can be decreased when combined with Armodafinil.
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Fosphenytoin resulting in a loss in efficacy.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fosphenytoin.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fosphenytoin.
AstemizoleThe metabolism of Astemizole can be increased when combined with Fosphenytoin.
AtazanavirThe metabolism of Atazanavir can be increased when combined with Fosphenytoin.
AtomoxetineThe metabolism of Atomoxetine can be increased when combined with Fosphenytoin.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Fosphenytoin.
Atracurium besylateFosphenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.
AvanafilThe metabolism of Avanafil can be increased when combined with Fosphenytoin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Fosphenytoin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fosphenytoin.
AzelastineFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fosphenytoin.
AzelnidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Azelnidipine.
AzimilideThe serum concentration of Fosphenytoin can be increased when it is combined with Azimilide.
AzithromycinThe metabolism of Azithromycin can be increased when combined with Fosphenytoin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fosphenytoin.
Bafilomycin A1The serum concentration of Bafilomycin A1 can be decreased when it is combined with Fosphenytoin.
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Fosphenytoin.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fosphenytoin.
BarnidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Barnidipine.
BazedoxifeneThe serum concentration of Bazedoxifene can be decreased when it is combined with Fosphenytoin.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Fosphenytoin.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Fosphenytoin.
BenidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Benidipine.
BenzatropineThe metabolism of Benzatropine can be increased when combined with Fosphenytoin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fosphenytoin.
Benzoic AcidThe serum concentration of Benzoic Acid can be decreased when it is combined with Fosphenytoin.
BenzphetamineThe metabolism of Benzphetamine can be increased when combined with Fosphenytoin.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fosphenytoin.
BepridilThe serum concentration of Fosphenytoin can be increased when it is combined with Bepridil.
BeraprostThe metabolism of Beraprost can be increased when combined with Fosphenytoin.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Fosphenytoin.
BexaroteneThe metabolism of Bexarotene can be increased when combined with Fosphenytoin.
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Fosphenytoin.
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Fosphenytoin.
BifonazoleThe serum concentration of Bifonazole can be decreased when it is combined with Fosphenytoin.
BisoprololThe metabolism of Bisoprolol can be increased when combined with Fosphenytoin.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Fosphenytoin.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Fosphenytoin.
BortezomibThe metabolism of Fosphenytoin can be decreased when combined with Bortezomib.
BosentanThe metabolism of Bosentan can be increased when combined with Fosphenytoin.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Fosphenytoin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Fosphenytoin.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
BrimonidineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Brimonidine.
BrinzolamideThe metabolism of Brinzolamide can be increased when combined with Fosphenytoin.
BromazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Bromazepam.
BromazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Bromazepam.
BromocriptineThe metabolism of Bromocriptine can be increased when combined with Fosphenytoin.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fosphenytoin.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fosphenytoin.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Fosphenytoin.
BumetanideFosphenytoin may decrease the diuretic activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fosphenytoin.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fosphenytoin.
BupropionThe metabolism of Bupropion can be increased when combined with Fosphenytoin.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fosphenytoin.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Fosphenytoin.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fosphenytoin.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fosphenytoin.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fosphenytoin.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fosphenytoin.
ButenafineThe serum concentration of Butenafine can be decreased when it is combined with Fosphenytoin.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fosphenytoin.
ButoconazoleThe serum concentration of Butoconazole can be decreased when it is combined with Fosphenytoin.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fosphenytoin.
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Fosphenytoin.
CabergolineThe metabolism of Cabergoline can be increased when combined with Fosphenytoin.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Fosphenytoin.
CaffeineThe metabolism of Caffeine can be increased when combined with Fosphenytoin.
CalcitriolThe metabolism of Calcitriol can be increased when combined with Fosphenytoin.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.
CandesartanThe metabolism of Candesartan can be increased when combined with Fosphenytoin.
CandicidinThe serum concentration of Candicidin can be decreased when it is combined with Fosphenytoin.
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Fosphenytoin.
CapecitabineThe serum concentration of Fosphenytoin can be increased when it is combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fosphenytoin.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fosphenytoin.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fosphenytoin.
CariprazineThe metabolism of Cariprazine can be increased when combined with Fosphenytoin.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fosphenytoin.
CarvedilolThe metabolism of Carvedilol can be increased when combined with Fosphenytoin.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Fosphenytoin.
CefazolinThe protein binding of Fosphenytoin can be decreased when combined with Cefazolin.
CelecoxibThe metabolism of Celecoxib can be increased when combined with Fosphenytoin.
CeliprololThe metabolism of Celiprolol can be increased when combined with Fosphenytoin.
CephalexinThe metabolism of Cephalexin can be increased when combined with Fosphenytoin.
CeritinibThe serum concentration of Fosphenytoin can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Fosphenytoin.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Fosphenytoin.
CeruleninThe serum concentration of Cerulenin can be decreased when it is combined with Fosphenytoin.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fosphenytoin.
CevimelineThe metabolism of Cevimeline can be increased when combined with Fosphenytoin.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Fosphenytoin.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fosphenytoin.
ChloramphenicolThe metabolism of Fosphenytoin can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe serum concentration of Fosphenytoin can be increased when it is combined with Chlordiazepoxide.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fosphenytoin.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fosphenytoin.
ChloroquineThe metabolism of Chloroquine can be increased when combined with Fosphenytoin.
ChloroxineThe serum concentration of Chloroxine can be decreased when it is combined with Fosphenytoin.
ChlorphenamineThe serum concentration of Fosphenytoin can be increased when it is combined with Chlorphenamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fosphenytoin.
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Fosphenytoin.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fosphenytoin.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fosphenytoin.
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Fosphenytoin.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Fosphenytoin.
CiclopiroxThe serum concentration of Ciclopirox can be decreased when it is combined with Fosphenytoin.
CilnidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Cilnidipine.
CilostazolThe metabolism of Cilostazol can be increased when combined with Fosphenytoin.
CimetidineThe metabolism of Fosphenytoin can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Fosphenytoin.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fosphenytoin.
CinnarizineThe serum concentration of Fosphenytoin can be increased when it is combined with Cinnarizine.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Fosphenytoin.
CiprofloxacinFosphenytoin may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be increased when combined with Fosphenytoin.
CitalopramThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Citalopram.
CitalopramThe metabolism of Fosphenytoin can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Fosphenytoin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fosphenytoin.
ClevidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fosphenytoin.
ClindamycinThe metabolism of Clindamycin can be increased when combined with Fosphenytoin.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fosphenytoin.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Fosphenytoin.
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Fosphenytoin.
ClofazimineThe metabolism of Clofazimine can be increased when combined with Fosphenytoin.
ClofibrateThe metabolism of Clofibrate can be increased when combined with Fosphenytoin.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fosphenytoin.
ClomipramineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Clomipramine.
ClonazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Clonazepam.
ClonazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fosphenytoin.
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Fosphenytoin.
ClorazepateThe serum concentration of Fosphenytoin can be increased when it is combined with Clorazepate.
ClorazepateThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Clorazepate.
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Fosphenytoin.
ClotrimazoleThe serum concentration of Clotrimazole can be decreased when it is combined with Fosphenytoin.
ClotrimazoleThe metabolism of Fosphenytoin can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Fosphenytoin.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fosphenytoin.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Fosphenytoin.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Fosphenytoin.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fosphenytoin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fosphenytoin.
Coenzyme Q10The serum concentration of Coenzyme Q10 can be decreased when it is combined with Fosphenytoin.
ColchicineThe metabolism of Colchicine can be increased when combined with Fosphenytoin.
ConivaptanThe metabolism of Conivaptan can be increased when combined with Fosphenytoin.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be increased when combined with Fosphenytoin.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Fosphenytoin.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Fosphenytoin.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fosphenytoin.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fosphenytoin.
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Fosphenytoin.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.
CyclosporineThe metabolism of Fosphenytoin can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fosphenytoin.
CytarabineThe metabolism of Cytarabine can be increased when combined with Fosphenytoin.
DabrafenibThe serum concentration of Fosphenytoin can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be increased when combined with Fosphenytoin.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Fosphenytoin.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fosphenytoin.
DapagliflozinThe metabolism of Dapagliflozin can be increased when combined with Fosphenytoin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fosphenytoin.
DapoxetineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Dapoxetine.
DapsoneThe metabolism of Dapsone can be increased when combined with Fosphenytoin.
DarifenacinThe metabolism of Darifenacin can be increased when combined with Fosphenytoin.
DarodipineThe serum concentration of Fosphenytoin can be increased when it is combined with Darodipine.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Fosphenytoin.
DasabuvirThe metabolism of Dasabuvir can be increased when combined with Fosphenytoin.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Fosphenytoin.
DaunorubicinThe metabolism of Daunorubicin can be increased when combined with Fosphenytoin.
Decanoic AcidThe serum concentration of Decanoic Acid can be decreased when it is combined with Fosphenytoin.
DeferasiroxThe serum concentration of Fosphenytoin can be increased when it is combined with Deferasirox.
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Fosphenytoin.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Fosphenytoin.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Fosphenytoin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Fosphenytoin.
DelavirdineThe metabolism of Fosphenytoin can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Fosphenytoin.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fosphenytoin.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fosphenytoin.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fosphenytoin.
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Fosphenytoin.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Fosphenytoin.
DesvenlafaxineThe metabolism of Desvenlafaxine can be increased when combined with Fosphenytoin.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fosphenytoin.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Fosphenytoin.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Fosphenytoin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fosphenytoin.
DexmethylphenidateThe serum concentration of Fosphenytoin can be increased when it is combined with Dexmethylphenidate.
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Fosphenytoin.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fosphenytoin.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fosphenytoin.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fosphenytoin.
DiazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Diazepam.
DiazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Diazepam.
DiazoxideThe serum concentration of Fosphenytoin can be decreased when it is combined with Diazoxide.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Fosphenytoin.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Fosphenytoin.
DicoumarolFosphenytoin may increase the anticoagulant activities of Dicoumarol.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Fosphenytoin.
DifenoxinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Difenoxin.
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Fosphenytoin.
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Fosphenytoin.
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Fosphenytoin.
DigitoxinThe metabolism of Digitoxin can be increased when combined with Fosphenytoin.
DigoxinThe metabolism of Digoxin can be increased when combined with Fosphenytoin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fosphenytoin.
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Fosphenytoin.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fosphenytoin.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fosphenytoin.
DiltiazemThe serum concentration of Fosphenytoin can be increased when it is combined with Diltiazem.
DiltiazemThe metabolism of Diltiazem can be increased when combined with Fosphenytoin.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fosphenytoin.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fosphenytoin.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fosphenytoin.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Fosphenytoin.
DisopyramideThe metabolism of Disopyramide can be increased when combined with Fosphenytoin.
DisulfiramThe serum concentration of Fosphenytoin can be increased when it is combined with Disulfiram.
DisulfiramThe metabolism of Disulfiram can be increased when combined with Fosphenytoin.
DocetaxelThe metabolism of Docetaxel can be increased when combined with Fosphenytoin.
DofetilideThe metabolism of Dofetilide can be increased when combined with Fosphenytoin.
DolasetronThe metabolism of Dolasetron can be increased when combined with Fosphenytoin.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Fosphenytoin.
DomperidoneThe metabolism of Domperidone can be increased when combined with Fosphenytoin.
DonepezilThe metabolism of Donepezil can be increased when combined with Fosphenytoin.
DopamineThe metabolism of Dopamine can be increased when combined with Fosphenytoin.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fosphenytoin.
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Fosphenytoin.
DotarizineThe serum concentration of Fosphenytoin can be increased when it is combined with Dotarizine.
DoxazosinThe metabolism of Doxazosin can be increased when combined with Fosphenytoin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fosphenytoin.
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Fosphenytoin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Fosphenytoin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Fosphenytoin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
DoxylamineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Fosphenytoin.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Fosphenytoin.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Fosphenytoin.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fosphenytoin.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fosphenytoin.
DutasterideThe metabolism of Dutasteride can be increased when combined with Fosphenytoin.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fosphenytoin.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Fosphenytoin.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fosphenytoin.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fosphenytoin.
EconazoleThe serum concentration of Econazole can be decreased when it is combined with Fosphenytoin.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fosphenytoin.
EfinaconazoleThe serum concentration of Efinaconazole can be decreased when it is combined with Fosphenytoin.
EfonidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Efonidipine.
EletriptanThe metabolism of Eletriptan can be increased when combined with Fosphenytoin.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Fosphenytoin.
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Fosphenytoin.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Fosphenytoin.
EnalaprilThe metabolism of Enalapril can be increased when combined with Fosphenytoin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fosphenytoin.
EnfuvirtideThe metabolism of Enfuvirtide can be increased when combined with Fosphenytoin.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fosphenytoin.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Fosphenytoin.
EperisoneThe serum concentration of Fosphenytoin can be increased when it is combined with Eperisone.
EpinastineThe metabolism of Epinastine can be increased when combined with Fosphenytoin.
EplerenoneThe metabolism of Eplerenone can be increased when combined with Fosphenytoin.
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Fosphenytoin.
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Fosphenytoin.
EquilinThe serum concentration of Equilin can be decreased when it is combined with Fosphenytoin.
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Fosphenytoin.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Fosphenytoin.
ErgonovineThe metabolism of Ergonovine can be increased when combined with Fosphenytoin.
ErgotamineThe metabolism of Ergotamine can be increased when combined with Fosphenytoin.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Fosphenytoin.
ErythromycinThe metabolism of Erythromycin can be increased when combined with Fosphenytoin.
EscitalopramThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Fosphenytoin.
Eslicarbazepine acetateThe metabolism of Fosphenytoin can be decreased when combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Fosphenytoin.
EstazolamThe serum concentration of Fosphenytoin can be increased when it is combined with Estazolam.
EstazolamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Estazolam.
EstradiolThe metabolism of Estradiol can be increased when combined with Fosphenytoin.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be increased when combined with Fosphenytoin.
EstramustineThe metabolism of Estramustine can be increased when combined with Fosphenytoin.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Fosphenytoin.
Estrone sulfateThe metabolism of Estrone sulfate can be increased when combined with Fosphenytoin.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fosphenytoin.
Etacrynic acidFosphenytoin may decrease the diuretic activities of Etacrynic acid.
EthanolFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fosphenytoin.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be increased when combined with Fosphenytoin.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
EthosuximideThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fosphenytoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Fosphenytoin.
Ethyl biscoumacetateFosphenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fosphenytoin.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fosphenytoin.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fosphenytoin.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fosphenytoin.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fosphenytoin.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fosphenytoin.
EtodolacThe metabolism of Etodolac can be increased when combined with Fosphenytoin.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fosphenytoin.
EtonogestrelThe metabolism of Etonogestrel can be increased when combined with Fosphenytoin.
EtoperidoneThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Fosphenytoin.
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Fosphenytoin.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fosphenytoin.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Fosphenytoin.
EtravirineThe metabolism of Fosphenytoin can be decreased when combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Fosphenytoin.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Fosphenytoin.
EzogabineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ezogabine.
FamciclovirThe metabolism of Famciclovir can be increased when combined with Fosphenytoin.
FamotidineThe metabolism of Famotidine can be increased when combined with Fosphenytoin.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Fosphenytoin.
FelodipineThe metabolism of Felodipine can be increased when combined with Fosphenytoin.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fosphenytoin.
FendilineThe serum concentration of Fosphenytoin can be increased when it is combined with Fendiline.
FenfluramineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Fenfluramine.
FenofibrateThe metabolism of Fenofibrate can be increased when combined with Fosphenytoin.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Fosphenytoin.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fosphenytoin.
FesoterodineThe metabolism of Fesoterodine can be increased when combined with Fosphenytoin.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fosphenytoin.
FinasterideThe metabolism of Finasteride can be increased when combined with Fosphenytoin.
FingolimodThe metabolism of Fingolimod can be increased when combined with Fosphenytoin.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Fosphenytoin.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fosphenytoin.
FloxuridineThe serum concentration of Fosphenytoin can be increased when it is combined with Floxuridine.
FluconazoleThe serum concentration of Fluconazole can be decreased when it is combined with Fosphenytoin.
FluconazoleThe metabolism of Fosphenytoin can be decreased when combined with Fluconazole.
FlucytosineThe serum concentration of Flucytosine can be decreased when it is combined with Fosphenytoin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fosphenytoin.
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Fosphenytoin.
FlumazenilThe serum concentration of Fosphenytoin can be increased when it is combined with Flumazenil.
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Fosphenytoin.
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Fosphenytoin.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fosphenytoin.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Fosphenytoin.
FlunitrazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Flunitrazepam.
FlunitrazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Flunitrazepam.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Fosphenytoin.
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Fosphenytoin.
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Fosphenytoin.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Fosphenytoin.
FluorouracilThe serum concentration of Fosphenytoin can be increased when it is combined with Fluorouracil.
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Fosphenytoin.
FluoxetineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Fluoxetine.
FluoxetineThe metabolism of Fosphenytoin can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fosphenytoin.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fosphenytoin.
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Fosphenytoin.
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Fosphenytoin.
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Fosphenytoin.
FlurazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Fosphenytoin.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fosphenytoin.
FlutamideThe metabolism of Flutamide can be increased when combined with Fosphenytoin.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Fosphenytoin.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fosphenytoin.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Fosphenytoin.
FluvastatinThe metabolism of Fosphenytoin can be decreased when combined with Fluvastatin.
FluvoxamineThe serum concentration of Fosphenytoin can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Fluvoxamine.
Folic AcidThe serum concentration of Fosphenytoin can be decreased when it is combined with Folic Acid.
FormoterolThe metabolism of Formoterol can be increased when combined with Fosphenytoin.
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be increased when combined with Fosphenytoin.
FurosemideFosphenytoin may decrease the diuretic activities of Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fosphenytoin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be increased when combined with Fosphenytoin.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fosphenytoin.
GavestinelThe metabolism of Gavestinel can be increased when combined with Fosphenytoin.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Fosphenytoin.
GemfibrozilThe metabolism of Gemfibrozil can be increased when combined with Fosphenytoin.
GliclazideThe metabolism of Gliclazide can be increased when combined with Fosphenytoin.
GlimepirideThe metabolism of Glimepiride can be increased when combined with Fosphenytoin.
GlipizideThe metabolism of Glipizide can be increased when combined with Fosphenytoin.
GlucosamineThe metabolism of Glucosamine can be increased when combined with Fosphenytoin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fosphenytoin.
GlyburideThe metabolism of Glyburide can be increased when combined with Fosphenytoin.
GlyphosateThe serum concentration of Glyphosate can be decreased when it is combined with Fosphenytoin.
GranisetronThe metabolism of Granisetron can be increased when combined with Fosphenytoin.
GrepafloxacinThe metabolism of Grepafloxacin can be increased when combined with Fosphenytoin.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Fosphenytoin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fosphenytoin.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fosphenytoin.
HalofantrineThe metabolism of Halofantrine can be increased when combined with Fosphenytoin.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fosphenytoin.
HaloproginThe serum concentration of Haloprogin can be decreased when it is combined with Fosphenytoin.
HalothaneThe serum concentration of Fosphenytoin can be increased when it is combined with Halothane.
HalothaneThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fosphenytoin.
HexetidineThe serum concentration of Hexetidine can be decreased when it is combined with Fosphenytoin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fosphenytoin.
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Fosphenytoin.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Fosphenytoin.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fosphenytoin.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Fosphenytoin.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fosphenytoin.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be increased when combined with Fosphenytoin.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
HydroxyzineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Fosphenytoin.
IbuprofenThe metabolism of Ibuprofen can be increased when combined with Fosphenytoin.
IdarubicinThe metabolism of Idarubicin can be increased when combined with Fosphenytoin.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Fosphenytoin.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Fosphenytoin.
IloperidoneThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Fosphenytoin.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fosphenytoin.
ImiquimodThe metabolism of Imiquimod can be increased when combined with Fosphenytoin.
IndacaterolThe metabolism of Indacaterol can be increased when combined with Fosphenytoin.
IndalpineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Indalpine.
IndapamideThe metabolism of Indapamide can be increased when combined with Fosphenytoin.
IndinavirThe metabolism of Indinavir can be increased when combined with Fosphenytoin.
indisulamThe metabolism of indisulam can be increased when combined with Fosphenytoin.
IndomethacinThe metabolism of Indomethacin can be increased when combined with Fosphenytoin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be increased when combined with Fosphenytoin.
IrbesartanThe metabolism of Fosphenytoin can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Fosphenytoin resulting in a loss in efficacy.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Fosphenytoin resulting in a loss in efficacy.
IsoconazoleThe serum concentration of Isoconazole can be decreased when it is combined with Fosphenytoin.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fosphenytoin.
IsoniazidThe metabolism of Fosphenytoin can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be increased when combined with Fosphenytoin.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be increased when combined with Fosphenytoin.
IsradipineThe serum concentration of Fosphenytoin can be increased when it is combined with Isradipine.
IsradipineThe metabolism of Isradipine can be increased when combined with Fosphenytoin.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Fosphenytoin.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Fosphenytoin.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Fosphenytoin.
IvermectinThe metabolism of Ivermectin can be increased when combined with Fosphenytoin.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Fosphenytoin.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Fosphenytoin.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fosphenytoin.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fosphenytoin.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fosphenytoin.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Fosphenytoin.
KetoconazoleThe metabolism of Fosphenytoin can be decreased when combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Fosphenytoin.
LacidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Lacidipine.
LacosamideThe serum concentration of Lacosamide can be decreased when it is combined with Fosphenytoin.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fosphenytoin.
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Fosphenytoin.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Fosphenytoin.
LapatinibThe metabolism of Fosphenytoin can be decreased when combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be increased when combined with Fosphenytoin.
LeflunomideThe metabolism of Fosphenytoin can be decreased when combined with Leflunomide.
LenvatinibThe metabolism of Lenvatinib can be increased when combined with Fosphenytoin.
LercanidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Lercanidipine.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Fosphenytoin.
LesinuradThe metabolism of Lesinurad can be increased when combined with Fosphenytoin.
LetrozoleThe metabolism of Letrozole can be increased when combined with Fosphenytoin.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fosphenytoin.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fosphenytoin.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Fosphenytoin.
LevocetirizineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Levocetirizine.
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Fosphenytoin.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Fosphenytoin.
LevomefolateThe serum concentration of Fosphenytoin can be decreased when it is combined with Levomefolate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fosphenytoin.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Levomilnacipran.
LevonorgestrelThe metabolism of Levonorgestrel can be increased when combined with Fosphenytoin.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fosphenytoin.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Fosphenytoin.
LicofeloneThe metabolism of Licofelone can be increased when combined with Fosphenytoin.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fosphenytoin.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Fosphenytoin.
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Fosphenytoin.
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Fosphenytoin.
LisurideThe metabolism of Lisuride can be increased when combined with Fosphenytoin.
LithiumThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Fosphenytoin.
LomitapideThe metabolism of Lomitapide can be increased when combined with Fosphenytoin.
LoperamideThe metabolism of Loperamide can be increased when combined with Fosphenytoin.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Fosphenytoin.
LopinavirThe metabolism of Fosphenytoin can be increased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fosphenytoin.
LorazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Lorazepam.
LorazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lorazepam.
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Fosphenytoin.
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Fosphenytoin.
LosartanThe metabolism of Losartan can be increased when combined with Fosphenytoin.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Fosphenytoin.
LovastatinThe metabolism of Fosphenytoin can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fosphenytoin.
Lu AA21004The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lu AA21004.
LuliconazoleThe serum concentration of Fosphenytoin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Fosphenytoin can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Fosphenytoin.
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Fosphenytoin.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Fosphenytoin.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fosphenytoin.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Fosphenytoin.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Magnesium Sulfate.
MalathionThe metabolism of Malathion can be increased when combined with Fosphenytoin.
ManidipineThe serum concentration of Fosphenytoin can be increased when it is combined with Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fosphenytoin.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Fosphenytoin.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Fosphenytoin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fosphenytoin.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fosphenytoin.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be increased when combined with Fosphenytoin.
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Fosphenytoin.
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Fosphenytoin.
MefloquineThe therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Mefloquine.
MefloquineThe metabolism of Mefloquine can be increased when combined with Fosphenytoin.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fosphenytoin.
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Fosphenytoin.
MeloxicamThe metabolism of Meloxicam can be increased when combined with Fosphenytoin.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fosphenytoin.
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Fosphenytoin.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fosphenytoin.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fosphenytoin.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fosphenytoin.
MestranolThe metabolism of Mestranol can be increased when combined with Fosphenytoin.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fosphenytoin.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Fosphenytoin.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fosphenytoin.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fosphenytoin.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fosphenytoin.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fosphenytoin.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Fosphenytoin.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fosphenytoin.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fosphenytoin.
MethotrexateThe serum concentration of Fosphenytoin can be decreased when it is combined with Methotrexate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fosphenytoin.
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Fosphenytoin.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fosphenytoin.
MethsuximideThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Methsuximide.
MethylphenidateThe serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fosphenytoin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Fosphenytoin.
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Fosphenytoin.
MetoprololThe metabolism of Metoprolol can be increased when combined with Fosphenytoin.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Fosphenytoin.
MetyraponeThe serum concentration of Metyrapone can be decreased when it is combined with Fosphenytoin.
MetyrosineFosphenytoin may increase the sedative activities of Metyrosine.
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Fosphenytoin.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Fosphenytoin.
MianserinThe therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Mianserin.
MianserinThe metabolism of Mianserin can be increased when combined with Fosphenytoin.
MibefradilThe serum concentration of Fosphenytoin can be increased when it is combined with Mibefradil.
MibefradilThe metabolism of Mibefradil can be increased when combined with Fosphenytoin.
MicafunginThe serum concentration of Micafungin can be decreased when it is combined with Fosphenytoin.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Fosphenytoin.
MiconazoleThe serum concentration of Fosphenytoin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Fosphenytoin can be increased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Midazolam.
MifepristoneThe serum concentration of Fosphenytoin can be increased when it is combined with Mifepristone.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Fosphenytoin.
MilnacipranThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Milnacipran.
MiltefosineThe serum concentration of Miltefosine can be decreased when it is combined with Fosphenytoin.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
MirabegronThe metabolism of Mirabegron can be increased when combined with Fosphenytoin.
MirtazapineFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fosphenytoin.
MivacuriumFosphenytoin may decrease the neuromuscular blocking activities of Mivacurium.
MoclobemideThe metabolism of Moclobemide can be increased when combined with Fosphenytoin.
ModafinilThe metabolism of Modafinil can be increased when combined with Fosphenytoin.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fosphenytoin.
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Fosphenytoin.
MonensinThe serum concentration of Monensin can be decreased when it is combined with Fosphenytoin.
MontelukastThe metabolism of Montelukast can be increased when combined with Fosphenytoin.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fosphenytoin.
muraglitazarThe metabolism of muraglitazar can be increased when combined with Fosphenytoin.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Fosphenytoin.
MyxothiazolThe serum concentration of Myxothiazol can be decreased when it is combined with Fosphenytoin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
NabiloneThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Nabilone.
NaftifineThe serum concentration of Naftifine can be decreased when it is combined with Fosphenytoin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fosphenytoin.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Fosphenytoin.
NaloxoneThe metabolism of Naloxone can be increased when combined with Fosphenytoin.
NaproxenThe metabolism of Naproxen can be increased when combined with Fosphenytoin.
NatamycinThe serum concentration of Natamycin can be decreased when it is combined with Fosphenytoin.
NateglinideThe metabolism of Nateglinide can be increased when combined with Fosphenytoin.
NefazodoneThe metabolism of Nefazodone can be increased when combined with Fosphenytoin.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Fosphenytoin.
NelfinavirThe metabolism of Fosphenytoin can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Fosphenytoin.
NevirapineThe metabolism of Nevirapine can be increased when combined with Fosphenytoin.
NicardipineThe metabolism of Nicardipine can be increased when combined with Fosphenytoin.
NiclosamideThe metabolism of Niclosamide can be increased when combined with Fosphenytoin.
NicotineThe metabolism of Nicotine can be increased when combined with Fosphenytoin.
NifedipineThe serum concentration of Fosphenytoin can be increased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Fosphenytoin.
NiguldipineThe serum concentration of Fosphenytoin can be increased when it is combined with Niguldipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Fosphenytoin.
NilotinibThe metabolism of Fosphenytoin can be decreased when combined with Nilotinib.
NiludipineThe serum concentration of Fosphenytoin can be increased when it is combined with Niludipine.
NilutamideThe metabolism of Nilutamide can be increased when combined with Fosphenytoin.
NilvadipineThe serum concentration of Fosphenytoin can be increased when it is combined with Nilvadipine.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Fosphenytoin.
NimesulideThe serum concentration of Fosphenytoin can be increased when it is combined with Nimesulide.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Fosphenytoin.
NimodipineThe serum concentration of Fosphenytoin can be increased when it is combined with Nimodipine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Fosphenytoin.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Fosphenytoin.
NisoldipineThe serum concentration of Fosphenytoin can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Nitrazepam.
NitrendipineThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Fosphenytoin.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fosphenytoin.
NitroxolineThe serum concentration of Nitroxoline can be decreased when it is combined with Fosphenytoin.
NorethisteroneThe metabolism of Norethisterone can be increased when combined with Fosphenytoin.
NorgestrelThe metabolism of Norgestrel can be increased when combined with Fosphenytoin.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Fosphenytoin.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fosphenytoin.
NystatinThe serum concentration of Nystatin can be decreased when it is combined with Fosphenytoin.
OlanzapineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Fosphenytoin.
OlodaterolThe metabolism of Olodaterol can be increased when combined with Fosphenytoin.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fosphenytoin.
OmbitasvirThe metabolism of Ombitasvir can be increased when combined with Fosphenytoin.
OmeprazoleThe serum concentration of Fosphenytoin can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Fosphenytoin.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fosphenytoin.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Fosphenytoin.
OrlistatThe serum concentration of Fosphenytoin can be decreased when it is combined with Orlistat.
OrphenadrineFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fosphenytoin.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fosphenytoin.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Fosphenytoin.
OspemifeneThe metabolism of Ospemifene can be increased when combined with Fosphenytoin.
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Fosphenytoin.
OxazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Oxazepam.
OxazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Oxazepam.
OxcarbazepineThe serum concentration of the active metabolites of Oxcarbazepine can be reduced when Oxcarbazepine is used in combination with Fosphenytoin resulting in a loss in efficacy.
OxiconazoleThe serum concentration of Oxiconazole can be decreased when it is combined with Fosphenytoin.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fosphenytoin.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fosphenytoin.
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Fosphenytoin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fosphenytoin.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fosphenytoin.
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Fosphenytoin.
pafuramidineThe serum concentration of pafuramidine can be decreased when it is combined with Fosphenytoin.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Fosphenytoin.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fosphenytoin.
PalonosetronThe metabolism of Palonosetron can be increased when combined with Fosphenytoin.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Fosphenytoin.
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Fosphenytoin.
ParaldehydeFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fosphenytoin.
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Fosphenytoin.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Fosphenytoin.
ParecoxibThe metabolism of Parecoxib can be increased when combined with Fosphenytoin.
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Fosphenytoin.
ParitaprevirThe metabolism of Paritaprevir can be increased when combined with Fosphenytoin.
ParoxetineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Fosphenytoin.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Fosphenytoin.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fosphenytoin.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fosphenytoin.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Fosphenytoin.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Fosphenytoin.
PergolideThe metabolism of Pergolide can be increased when combined with Fosphenytoin.
PerhexilineThe serum concentration of Fosphenytoin can be increased when it is combined with Perhexiline.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Fosphenytoin.
PermethrinThe metabolism of Permethrin can be increased when combined with Fosphenytoin.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fosphenytoin.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fosphenytoin.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Fosphenytoin.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fosphenytoin.
PhenacetinThe metabolism of Phenacetin can be increased when combined with Fosphenytoin.
PhenindioneFosphenytoin may increase the anticoagulant activities of Phenindione.
PhenobarbitalFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fosphenytoin.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be increased when combined with Fosphenytoin.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fosphenytoin.
PhenprocoumonFosphenytoin may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Fosphenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fosphenytoin.
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Fosphenytoin.
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Fosphenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fosphenytoin.
PinacidilThe metabolism of Pinacidil can be increased when combined with Fosphenytoin.
PinaveriumThe serum concentration of Fosphenytoin can be increased when it is combined with Pinaverium.
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Fosphenytoin.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fosphenytoin.
PipotiazineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Pipotiazine.
PirenzepineThe serum concentration of Fosphenytoin can be increased when it is combined with Pirenzepine.
PiretanideFosphenytoin may decrease the diuretic activities of Piretanide.
PiroxicamThe metabolism of Piroxicam can be increased when combined with Fosphenytoin.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Fosphenytoin.
PizotifenThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Pizotifen.
PodofiloxThe metabolism of Podofilox can be increased when combined with Fosphenytoin.
PomalidomideThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Pomalidomide.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Fosphenytoin.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Fosphenytoin.
PramipexoleFosphenytoin may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fosphenytoin.
PrasugrelThe metabolism of Prasugrel can be increased when combined with Fosphenytoin.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Fosphenytoin.
PrazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Prazepam.
PrazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Prazepam.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Fosphenytoin.
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Fosphenytoin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Fosphenytoin.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Fosphenytoin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fosphenytoin.
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Fosphenytoin.
PrenylamineThe serum concentration of Fosphenytoin can be increased when it is combined with Prenylamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fosphenytoin.
PrimaquineThe metabolism of Primaquine can be increased when combined with Fosphenytoin.
PrimidoneThe metabolism of Primidone can be increased when combined with Fosphenytoin.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fosphenytoin.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fosphenytoin.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fosphenytoin.
ProgesteroneThe metabolism of Progesterone can be increased when combined with Fosphenytoin.
ProguanilThe metabolism of Proguanil can be increased when combined with Fosphenytoin.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fosphenytoin.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fosphenytoin.
PropacetamolThe serum concentration of the active metabolites of Propacetamol can be reduced when Propacetamol is used in combination with Fosphenytoin resulting in a loss in efficacy.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Fosphenytoin.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fosphenytoin.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fosphenytoin.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fosphenytoin.
PropranololThe metabolism of Propranolol can be increased when combined with Fosphenytoin.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fosphenytoin.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fosphenytoin.
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Fosphenytoin.
PyridoxineThe metabolism of Fosphenytoin can be increased when combined with Pyridoxine.
PyrimethamineThe metabolism of Fosphenytoin can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fosphenytoin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fosphenytoin.
QuinacrineThe metabolism of Quinacrine can be increased when combined with Fosphenytoin.
QuinidineFosphenytoin may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Fosphenytoin.
QuinineThe metabolism of Fosphenytoin can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Fosphenytoin.
RadicicolThe serum concentration of Radicicol can be decreased when it is combined with Fosphenytoin.
RaloxifeneThe metabolism of Raloxifene can be increased when combined with Fosphenytoin.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fosphenytoin.
RanitidineThe metabolism of Ranitidine can be increased when combined with Fosphenytoin.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Fosphenytoin.
RapacuroniumFosphenytoin may decrease the neuromuscular blocking activities of Rapacuronium.
ReboxetineThe metabolism of Reboxetine can be increased when combined with Fosphenytoin.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Fosphenytoin.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosphenytoin.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fosphenytoin.
RepaglinideThe metabolism of Repaglinide can be increased when combined with Fosphenytoin.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fosphenytoin.
RetapamulinThe metabolism of Retapamulin can be increased when combined with Fosphenytoin.
RifabutinThe metabolism of Rifabutin can be increased when combined with Fosphenytoin.
RifampicinThe serum concentration of Fosphenytoin can be decreased when it is combined with Rifampicin.
RifampicinThe metabolism of Rifampicin can be increased when combined with Fosphenytoin.
RifapentineThe metabolism of Fosphenytoin can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Fosphenytoin.
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Fosphenytoin.
RimonabantThe metabolism of Rimonabant can be increased when combined with Fosphenytoin.
RiociguatThe metabolism of Riociguat can be increased when combined with Fosphenytoin.
RisedronateThe serum concentration of Fosphenytoin can be increased when it is combined with Risedronate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fosphenytoin.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Fosphenytoin.
RitonavirThe metabolism of Fosphenytoin can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Fosphenytoin.
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Fosphenytoin.
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Fosphenytoin.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Fosphenytoin.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Fosphenytoin.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fosphenytoin.
RopiniroleFosphenytoin may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fosphenytoin.
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Fosphenytoin.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Fosphenytoin.
RotigotineFosphenytoin may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Fosphenytoin.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fosphenytoin.
RufinamideThe serum concentration of Rufinamide can be decreased when it is combined with Fosphenytoin.
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Fosphenytoin.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fosphenytoin.
Salicylhydroxamic AcidThe serum concentration of Salicylhydroxamic Acid can be decreased when it is combined with Fosphenytoin.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Fosphenytoin.
SalmeterolThe metabolism of Salmeterol can be increased when combined with Fosphenytoin.
SaquinavirThe metabolism of Saquinavir can be increased when combined with Fosphenytoin.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Fosphenytoin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fosphenytoin.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fosphenytoin.
SelegilineThe metabolism of Selegiline can be increased when combined with Fosphenytoin.
SelexipagThe metabolism of Selexipag can be increased when combined with Fosphenytoin.
SeratrodastThe metabolism of Seratrodast can be increased when combined with Fosphenytoin.
SertaconazoleThe serum concentration of Sertaconazole can be decreased when it is combined with Fosphenytoin.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fosphenytoin.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Fosphenytoin.
SertralineThe metabolism of Fosphenytoin can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fosphenytoin.
SibutramineThe metabolism of Sibutramine can be increased when combined with Fosphenytoin.
SildenafilThe metabolism of Sildenafil can be increased when combined with Fosphenytoin.
SilodosinThe metabolism of Silodosin can be increased when combined with Fosphenytoin.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Fosphenytoin.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Fosphenytoin.
SinefunginThe serum concentration of Sinefungin can be decreased when it is combined with Fosphenytoin.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Fosphenytoin.
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Fosphenytoin.
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Fosphenytoin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Fosphenytoin.
SolifenacinThe metabolism of Solifenacin can be increased when combined with Fosphenytoin.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Fosphenytoin.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Fosphenytoin.
SorafenibThe metabolism of Fosphenytoin can be decreased when combined with Sorafenib.
SpiramycinThe metabolism of Spiramycin can be increased when combined with Fosphenytoin.
StiripentolThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fosphenytoin.
SulconazoleThe serum concentration of Sulconazole can be decreased when it is combined with Fosphenytoin.
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Fosphenytoin.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Fosphenytoin.
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Fosphenytoin.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Fosphenytoin.
SulfisoxazoleThe metabolism of Sulfisoxazole can be increased when combined with Fosphenytoin.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fosphenytoin.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Fosphenytoin.
SuprofenThe metabolism of Suprofen can be increased when combined with Fosphenytoin.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Fosphenytoin.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Fosphenytoin.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Fosphenytoin.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Fosphenytoin.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Fosphenytoin.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Fosphenytoin.
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Fosphenytoin.
TamsulosinThe metabolism of Tamsulosin can be increased when combined with Fosphenytoin.
TapentadolThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tapentadol.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Fosphenytoin.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fosphenytoin.
TasosartanThe metabolism of Tasosartan can be increased when combined with Fosphenytoin.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Fosphenytoin.
TavaboroleThe serum concentration of Tavaborole can be decreased when it is combined with Fosphenytoin.
TazaroteneThe metabolism of Tazarotene can be increased when combined with Fosphenytoin.
TegafurThe serum concentration of Fosphenytoin can be increased when it is combined with Tegafur.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fosphenytoin.
TelaprevirThe serum concentration of Fosphenytoin can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Telithromycin can be increased when combined with Fosphenytoin.
TemazepamThe serum concentration of Fosphenytoin can be increased when it is combined with Temazepam.
TemazepamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Temazepam.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Fosphenytoin.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Fosphenytoin.
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Fosphenytoin.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Fosphenytoin.
TerconazoleThe serum concentration of Terconazole can be decreased when it is combined with Fosphenytoin.
TerfenadineThe metabolism of Terfenadine can be increased when combined with Fosphenytoin.
TeriflunomideThe metabolism of Fosphenytoin can be decreased when combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Fosphenytoin.
TestosteroneThe metabolism of Testosterone can be increased when combined with Fosphenytoin.
TetrabenazineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fosphenytoin.
TetracyclineThe metabolism of Tetracycline can be increased when combined with Fosphenytoin.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fosphenytoin.
ThalidomideFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fosphenytoin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Fosphenytoin.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fosphenytoin.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fosphenytoin.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fosphenytoin.
ThiotepaThe metabolism of Thiotepa can be increased when combined with Fosphenytoin.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fosphenytoin.
ThymolThe serum concentration of Thymol can be decreased when it is combined with Fosphenytoin.
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Fosphenytoin.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fosphenytoin.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Fosphenytoin resulting in a loss in efficacy.
TicagrelorThe metabolism of Fosphenytoin can be decreased when combined with Ticagrelor.
TiclopidineThe serum concentration of Fosphenytoin can be increased when it is combined with Ticlopidine.
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Fosphenytoin.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fosphenytoin.
TimololThe metabolism of Timolol can be increased when combined with Fosphenytoin.
TinidazoleThe metabolism of Tinidazole can be increased when combined with Fosphenytoin.
TioconazoleThe serum concentration of Tioconazole can be decreased when it is combined with Fosphenytoin.
TiotropiumThe metabolism of Tiotropium can be increased when combined with Fosphenytoin.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Fosphenytoin.
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Fosphenytoin.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fosphenytoin.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Fosphenytoin.
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Fosphenytoin.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosphenytoin.
Tolfenamic AcidThe serum concentration of Fosphenytoin can be increased when it is combined with Tolfenamic Acid.
TolnaftateThe serum concentration of Tolnaftate can be decreased when it is combined with Fosphenytoin.
TolterodineThe metabolism of Tolterodine can be increased when combined with Fosphenytoin.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Fosphenytoin.
TopiramateThe serum concentration of Topiramate can be decreased when it is combined with Fosphenytoin.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fosphenytoin.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Fosphenytoin.
TorasemideFosphenytoin may decrease the diuretic activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Fosphenytoin.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Fosphenytoin.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fosphenytoin.
TranilastThe serum concentration of Fosphenytoin can be increased when it is combined with Tranilast.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fosphenytoin.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fosphenytoin.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be increased when combined with Fosphenytoin.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Fosphenytoin.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fosphenytoin.
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Fosphenytoin.
TretinoinThe metabolism of Tretinoin can be increased when combined with Fosphenytoin.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Fosphenytoin.
TriazolamThe serum concentration of Fosphenytoin can be increased when it is combined with Triazolam.
TriazolamThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fosphenytoin.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fosphenytoin.
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Fosphenytoin.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Fosphenytoin.
TrimethoprimThe metabolism of Fosphenytoin can be decreased when combined with Trimethoprim.
TrimetrexateThe serum concentration of Trimetrexate can be decreased when it is combined with Fosphenytoin.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fosphenytoin.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fosphenytoin.
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Fosphenytoin.
TroleandomycinThe metabolism of Troleandomycin can be increased when combined with Fosphenytoin.
UdenafilThe metabolism of Udenafil can be increased when combined with Fosphenytoin.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Fosphenytoin.
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Fosphenytoin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fosphenytoin.
ValsartanThe metabolism of Fosphenytoin can be decreased when combined with Valsartan.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Fosphenytoin.
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Fosphenytoin.
VardenafilThe metabolism of Vardenafil can be increased when combined with Fosphenytoin.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Fosphenytoin.
VenlafaxineThe metabolism of Venlafaxine can be increased when combined with Fosphenytoin.
VerapamilThe serum concentration of Fosphenytoin can be increased when it is combined with Verapamil.
VerapamilThe metabolism of Verapamil can be increased when combined with Fosphenytoin.
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Fosphenytoin.
VigabatrinThe serum concentration of Fosphenytoin can be decreased when it is combined with Vigabatrin.
VigabatrinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Vigabatrin.
VilanterolThe metabolism of Vilanterol can be increased when combined with Fosphenytoin.
VilazodoneThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Vilazodone.
VinblastineThe metabolism of Vinblastine can be increased when combined with Fosphenytoin.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Fosphenytoin.
VindesineThe metabolism of Vindesine can be increased when combined with Fosphenytoin.
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Fosphenytoin.
VismodegibThe metabolism of Vismodegib can be increased when combined with Fosphenytoin.
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Fosphenytoin.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Fosphenytoin.
VoriconazoleThe metabolism of Fosphenytoin can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Vortioxetine.
WarfarinFosphenytoin may increase the anticoagulant activities of Warfarin.
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Fosphenytoin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fosphenytoin.
XylometazolineThe serum concentration of Fosphenytoin can be increased when it is combined with Xylometazoline.
YohimbineThe metabolism of Yohimbine can be increased when combined with Fosphenytoin.
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Fosphenytoin.
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Fosphenytoin.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fosphenytoin.
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Fosphenytoin.
ZiconotideThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be increased when combined with Fosphenytoin.
ZileutonThe metabolism of Zileuton can be increased when combined with Fosphenytoin.
ZimelidineThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fosphenytoin.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fosphenytoin.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fosphenytoin.
ZomepiracThe metabolism of Zomepirac can be increased when combined with Fosphenytoin.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Fosphenytoin.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fosphenytoin.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fosphenytoin.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fosphenytoin.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Fosphenytoin.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fosphenytoin.
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M: A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004 Mar;11(3):244-52. [PubMed:15001403 ]
  2. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M: Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010 Apr;9(4):413-24. doi: 10.1016/S1474-4422(10)70059-4. [PubMed:20298965 ]
  3. Lenkowski PW, Ko SH, Anderson JD, Brown ML, Patel MK: Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci. 2004 Apr;21(5):635-44. [PubMed:15066664 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Kim KA, Park JY: Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Drug Metab Dispos. 2003 Sep;31(9):1090-2. [PubMed:12920163 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Anderson GD: Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit. 2008 Apr;30(2):173-80. doi: 10.1097/FTD.0b013e318167d11b. [PubMed:18367977 ]
  2. Hennessy S, Leonard CE, Freeman CP, Metlay JP, Chu X, Strom BL, Bilker WB: CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009 Dec;49(12):1483-7. doi: 10.1177/0091270009343006. Epub 2009 Jul 17. [PubMed:19617466 ]
  3. Klotz U: The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 2007;46(4):271-9. [PubMed:17375979 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E: Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. Epub 2004 Apr 28. [PubMed:15123723 ]
  2. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL: Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58. [PubMed:14977870 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL: Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol. 2009 Jan-Feb;23(1):43-58. doi: 10.1002/jbt.20264. [PubMed:19202563 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55. [PubMed:11678778 ]
  4. Klotz U: The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 2007;46(4):271-9. [PubMed:17375979 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008 May;9(4):310-22. [PubMed:18473749 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Walker MC, Patsalos PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther. 1995;67(3):351-84. [PubMed:8577822 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 11:18 / Updated on August 17, 2016 12:23